Archives
-
Epalrestat Activates KEAP1/Nrf2 in Parkinson’s Disease
2026-08-14
Jia et al. report that Epalrestat protects dopaminergic neurons in cellular and mouse Parkinson’s disease models by reducing oxidative stress and mitochondrial dysfunction. The study’s central innovation is evidence that this aldose reductase inhibitor directly engages KEAP1, promoting KEAP1 degradation and activating Nrf2, although the findings remain preclinical.
-
Dehydroepiandrosterone (DHEA) Research Workflows
2026-08-14
Build reproducible DHEA assays for neural survival, stem-cell expansion, and ovarian steroidogenesis while separating protective signaling from PCOS-model induction. This guide combines concentration planning, mitochondrial readouts, and troubleshooting for better experimental interpretation.
-
Dorsomorphin (Compound C) Workflow Guide
2026-08-13
Dorsomorphin (Compound C) provides a reversible way to interrogate AMPK-dependent metabolism, autophagy regulation, and BMP/Smad signaling in the same experimental strategy. This practical guide translates the reference study’s time-resolved Nrf2 analysis into assay design, controls, and troubleshooting without treating Compound C as a universal pathway-specific probe.
-
Self-Amplifying RNA for Dose-Sparing Influenza Vaccines
2026-08-13
This study shows that self-amplifying RNA can overcome the weak influenza B immunogenicity observed with conventional mRNA vaccination in mice. Its dose-sparing and durability findings support platform-specific optimization of RNA vaccines while also highlighting why nucleoside chemistry, antigen design, and RNA architecture must be evaluated separately.
-
Annexin V-FITC/PI Apoptosis Assay Kit Guide
2026-08-12
The Annexin V-FITC/PI Apoptosis Assay Kit provides a practical two-parameter method for separating viable, early apoptotic, and membrane-compromised cells by fluorescence microscopy or flow cytometry. It is intended for research apoptosis assays and should not be used as a standalone diagnostic test or as proof of a specific cell-death pathway.
-
EPO mRNA: From Cap 1 Design to SCI Translation
2026-08-12
Targeted EPO mRNA delivery is reshaping how researchers approach spinal cord injury, neuroprotection, and erythropoiesis. A 2026 Materials Today Bio study used mannose-modified lipid nanoparticles to localize EPO mRNA to inflammatory macrophages and microglia, reducing ferroptosis-associated injury in mice. This article examines the mechanistic rationale, experimental design, translational limitations, and strategic value of EZ Cap™ EPO mRNA (ψUTP) as a defined RNA input for mammalian protein expression and therapeutic research.
-
Patient-Derived Gastric Cancer Assembloids
2026-08-11
This study develops a patient-specific gastric cancer assembloid by combining matched tumor organoids with tumor-derived stromal subpopulations. The model reveals that stromal composition alters gene expression and drug sensitivity, creating a more physiologically informative system for investigating tumor–stroma interactions and personalized treatment responses.
-
CPI-613: Mitochondrial Metabolism Workflows
2026-08-11
Build a reproducible CPI-613 workflow that connects mitochondrial carbon flux, apoptosis, and carefully controlled ferroptosis-related readouts. Practical dosing, orthogonal assays, formulation guidance, and troubleshooting help distinguish target-linked metabolic effects from nonspecific cytotoxicity.
-
Trametinib (GSK1120212) Assay Guide
2026-08-10
A scenario-based laboratory guide to using Trametinib (GSK1120212), SKU A3018, for MEK-ERK pathway modulation, cell-cycle analysis, and viability studies. It covers stock preparation, assay compatibility, interpretation of cytostasis versus apoptosis, and practical product-selection criteria supported by product data and recent pathway literature.
-
Bobcat339 in DNA Methylation Research
2026-08-09
Bobcat339 is a cytosine structure-based TET enzyme inhibitor for probing DNA methylation regulation and gene transcription modulation. This article presents an assay-centered framework for applying it to UHRF1-linked osteogenic dysfunction and senile osteoporosis research.
-
Rotigotine Workflows for Parkinson’s Disease Research
2026-08-08
Rotigotine supports both receptor-focused cell assays and route-resolved Parkinson’s disease models, including lower urinary tract studies. This guide translates published dosing data into practical preparation, cystometry, neuroprotection, and troubleshooting workflows.
-
ML133 HCl: A Mechanistic Guide to Kir2.1 Assays
2026-08-07
ML133 HCl is a selective potassium channel inhibitor for dissecting Kir2.1-dependent signaling in vascular smooth muscle. This guide connects channel pharmacology with pulmonary remodeling assays, practical controls, and evidence-based interpretation.
-
IGF2BP3–FZD1/7 Axis Drives Chemoresistance in TNBC Stem Cell
2026-08-07
This study uncovers how IGF2BP3, an m6A reader, stabilizes FZD1/7 transcripts and activates β-catenin signaling in triple-negative breast cancer stem cells, promoting stemness and carboplatin resistance. Targeting this IGF2BP3–FZD1/7 pathway may enhance therapeutic efficacy and reduce chemotherapy dosing in TNBC.
-
LY2228820: Advanced Insights into p38 MAP Kinase Inhibition
2026-08-06
Explore the scientific depth of LY2228820, a potent p38 MAP kinase inhibitor, including its unique anti-inflammatory and anti-angiogenic applications. This article provides advanced assay guidance and differentiates LY2228820’s value from existing protocols.
-
N-MYC/eIF4G1 Axis Controls Survival in inv(16) AML Cells
2026-08-06
This study uncovers a previously uncharacterized role for N-MYC in the survival of inv(16) acute myeloid leukemia cells, acting through regulation of the translation initiation factor eIF4G1. The identification of a novel MYCN enhancer and the oncogenic N-MYC/eIF4G1 axis provides new mechanistic insights and potential therapeutic targets for specific AML subtypes.